EMAIL THIS PAGE TO A FRIEND

A1362 Sigma

Agomelatine

≥98% (HPLC)

Synonym: N-[2-(7-Methoxy-1-naphthalenyl)ethyl]-acetamide, S-20098

  • CAS Number 138112-76-2

  • Empirical Formula (Hill Notation) C15H17NO2

  • Molecular Weight 243.30

  •  MDL number MFCD00916659

Purchase

Description

Biochem/physiol Actions

Agomelatine is an extremely potent agonist at both melatonin receptors (MT1 and MT2), with additional antagonism at 5HT2C. It is a novel antidepressant with many desired in vivo properties, including neuroprotection and neurogenesis in depression-sensitive brain areas. Agomelatine′s efficacy appears to be due to both melatonergic and serotonergic properties. In neurogenesis assays, both in vitro and in vivo, the compound effects were differentially affected by antagonists for MT1/MT2 and 5HT2C, demonstrating actions through all three receptors.

Features and Benefits

This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®,1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.

This compound is featured on the Melatonin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

LOPAC is a registered trademark of Sigma-Aldrich Co. LLC

Price and Availability

TruPAGE™ Pre-cast Polyacrylamide Gels


TruPAGE™ Pre-cast Polyacrylamide GelsTruPAGE Gels run true every time!

  • . 2-Year Shelf Life
  • . Superior Band Resolution
  • . Strong & Tear Resistant
  • . Higher Capacity Wells



Duolink Webinar

Customers Also Viewed

IIK7
I5531IIK7

solid

K1888K 185

solid

Luzindole

≥90%

Safety & Documentation

Safety Information

Symbol 
GHS09  GHS09
Signal word 
Warning
Hazard statements 
Precautionary statements 
Hazard Codes (Europe) 
N
Risk Statements (Europe) 
50
Safety Statements (Europe) 
61
RIDADR 
UN 3077 9 / PGIII
WGK Germany 
3

Documents

Certificate of Analysis

Protocols & Articles

Peer-Reviewed Papers

References

Set your institution to view full text papers.

A benefit-risk assessment of agomelatine in the treatment of major depression. Howland RH Drug Saf. 34(9), 709-31, (2011)

Loading...


Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Srinivasan V, De Berardis D, Shillcutt SD, et al. Expert Opin. Investig. Drugs 21(10), 1503-22, (2012)

Loading...


Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Koesters M, Guaiana G, Cipriani A, et al. Br. J. Psychiatry 203(3), 179-87, (2013)

Loading...


Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Kasper S, Corruble E, Hale A, et al. Int. Clin. Psychopharmacol. 28(1), 12-9, (2013)

Loading...


Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. Stein DJ, Ahokas A, Márquez MS, et al. J. Clin. Psychiatry 75(4), 362-8, (2014)

Loading...


[The activity of glutathione antioxidant system at melaksen and valdoxan action under experimental hyperthyroidism in rats]. Gorbenko MV, Popova TN, Shul'gin KK, et al. Biomed. Khim. 59(5), 541-9, (2013)

Loading...


[Approaches to treatment optimization of depression in patients with Parkinson's disease]. Strashunskaya EY and Strashunskaya EL Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 113(4), 75-9, (2013)

Loading...


Agomelatine: a review of adverse effects. Prescrire Int. 22(136), 70-1, (2013)

Loading...


Agomelatine, melatonin and depressive disorder. Norman TR Expert Opin. Investig. Drugs 22(4), 407-10, (2013)

Loading...


Agomelatine: clinical experience and adherence to EMA recommendations for a novel antidepressant. Sinnott C and Morris M Ir. Med. J. 106(2), 52-4, (2013)

Loading...


[Antidepressants in cardiology]. Kotov AM, Stotsky AD, and Kolesnikov DB Klin. Med. (Mosk.) 90(10), 11-6, (2012)

Loading...


Novel conformationally constrained analogues of agomelatine as new melatoninergic ligands. Rami M, Landagaray E, Ettaoussi M, et al. Molecules 18(1), 154-66, (2012)

Loading...


A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks. Sparshatt A, McAllister Williams RH, Baldwin DS, et al. Acta Psychiatr. Scand. 128(3), 203-11, (2013)

Loading...


[Valdoxan in the treatment of depression in neurological practice: results of the Russian multicenter naturalistic study "Resonance"]. Vorob'eva OV Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 112(9), 47-51, (2012)

Loading...


Relief of intractable posthypoxic myoclonus after administration of agomelatine. González de la Aleja J, Saiz-Díaz RA, and De la Peña P Clin. Neuropharmacol. 35(5), 258-9, (2012)

Loading...


Agomelatine for the treatment of major depressive disorder. Carney RM and Shelton RC Expert Opin. Pharmacother. 12(15), 2411-9, (2011)

Loading...


Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Soumier, A., et Al. Neuropsychopharmacology 34, 2390-2403, (2009)

Loading...


Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Descamps, A., et Al. Psychopharmacology 205, 93-106, (2009)

Loading...


Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity. Gressens, P., et Al. Eur. J. Pharmacol. 588, 58-63, (2008)

Loading...


Biological rhythms and melatonin in mood disorders and their treatments. Lanfumey L, Mongeau R, and Hamon M Pharmacol. Ther. 138(2), 176-84, (2013)

Loading...


Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. Stein DJ, Ahokas A, Albarran C, et al. J. Clin. Psychiatry 73(7), 1002-8, (2012)

Loading...


Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. Pompili M, Serafini G, Innamorati M, et al. World J. Biol. Psychiatry 14(6), 412-31, (2013)

Loading...


The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Montejo A, Majadas S, Rizvi SJ, et al. Hum. Psychopharmacol. Clin. Exp. 26(8), 537-42, (2011)

Loading...


Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. Racagni G, Riva MA, Molteni R, et al. World J. Biol. Psychiatry 12(8), 574-87, (2011)

Loading...


The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. De Berardis D, Di Iorio G, Acciavatti T, et al. CNS Neurol. Disord. Drug Targets 10(1), 119-32, (2011)

Loading...


Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine. Goodwin GM, Boyer P, Emsley R, et al. Int. Clin. Psychopharmacol. 28(1), 20-8, (2013)

Loading...


Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions. Martínez-Águila A, Fonseca B, Bergua A, et al. Eur. J. Pharmacol. 701(1-3), 213-7, (2013)

Loading...


Agomelatine: a narrative review. Demyttenaere K Eur. Neuropsychopharmacol. 21 Suppl 4, S703-9, (2011)

Loading...


Synergistic mechanisms involved in the antidepressant effects of agomelatine. Tardito D, Molteni R, Popoli M, et al. Eur. Neuropsychopharmacol. 22 Suppl 3, S482-6, (2012)

Loading...


Anhedonia and major depression: the role of agomelatine. Di Giannantonio M and Martinotti G Eur. Neuropsychopharmacol. 22 Suppl 3, S505-10, (2012)

Loading...


Agomelatine in depressive disorders: its novel mechanisms of action. Srinivasan V, Zakaria R, Othman Z, et al. J. Neuropsychiatry Clin. Neurosci. 24(3), 290-308, (2012)

Loading...


A review of preliminary observations on agomelatine in the treatment of anxiety disorders. Levitan MN, Papelbaum M, and Nardi AE Exp. Clin. Psychopharmacol. 20(6), 504-9, (2012)

Loading...


Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece. Maniadakis N, Kourlaba G, Mougiakos T, et al. BMC Health Serv. Res. 13, 173, (2013)

Loading...


Focus on agomelatine. Green B Curr. Med. Res. Opin. 27(4), 745-9, (2011)

Loading...


A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. Demyttenaere K, Corruble E, Hale A, et al. CNS Spectr. 18(3), 163-70, (2013)

Loading...


Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data. De Berardis D, Conti CM, Marini S, et al. Int. J. Immunopathol. Pharmacol. 26(2), 299-304, (2013)

Loading...


Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. Taylor D, Sparshatt A, Varma S, et al. BMJ 348, g1888, (2014)

Loading...


Agomelatine versus other antidepressive agents for major depression. Guaiana G, Gupta S, Chiodo D, et al. Cochrane Database Syst. Rev. 12, CD008851, (2013)

Loading...


Treatment of severe sleep disorder related to alcohol-dependence with high-dose agomelatine - a case report. Grosshans M, Mutschler J, and Kiefer F Psychiatr. Danub. 25(4), 416-8, (2013)

Loading...


Actigraphic assessment of sleep disturbances following traumatic brain injury. Sinclair KL, Ponsford J, and Rajaratnam SM Behav. Sleep Med. 12(1), 13-27, (2014)

Loading...


Agomelatine may improve REM sleep behavior disorder symptoms. Bonakis A, Economou NT, Papageorgiou SG, et al. J. Clin. Psychopharmacol. 32(5), 732-4, (2012)

Loading...


Two cases of delirium with agomelatine therapy. Viejo Sacha MG, De Ambrosi B, Muñoz C, et al. Ann. Clin. Psychiatry 25(1), 67-8, (2013)

Loading...


Agomelatine in depression. Smeraldi E and Delmonte D Expert Opin. Drug Saf. 12(6), 873-80, (2013)

Loading...


Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression? Jakovljević M Psychiatr. Danub. 23(1), 2-9, (2011)

Loading...


A possible new option for migraine management: agomelatine. Guglielmo R, Martinotti G, Di Giannantonio M, et al. Clin. Neuropharmacol. 36(2), 65-7, (2013)

Loading...


[Tachycardia and precordial pain with agomelatine: a case report]. Comte H, Auffret M, Lelièvre B, et al. Therapie. 68(5), 324-5, (2013)

Loading...


[Early effects of antidepressants]. Llorca PM Encephale 38 Suppl 2, S49-53, (2012)

Loading...


[Valdoxan (agomelatine) in the treatment of depression in patients with cerebrovascular diseases: the results of the Russian multicenter naturalistic study "Resonance"]. Pizova NV Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 112(12), 41-5, (2012)

Loading...


[A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder]. Tiuvina NA and Smirnova VN Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 112(11 Pt 2), 53-60, (2012)

Loading...


[Valdoxan (agomelatine) in combined therapy of moderate and severe non-psychotic depressions]. Medvedev VE Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 112(5), 37-40, (2012)

Loading...


[The combined therapy with valdoxan and amitriptyline of treatment resistant somatized depression]. Sobennikov VS and Prokop'eva ML Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 113(2), 20-4, (2013)

Loading...


Related Products

Technical Service:

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Bulk Ordering & Pricing:

Need larger quantities for your development, manufacturing or research applications?